216 related articles for article (PubMed ID: 32437019)
1. Baricitinib: A chance to treat COVID-19?
Lo Caputo S; Corso G; Clerici M; Santantonio TA
J Med Virol; 2020 Nov; 92(11):2343-2344. PubMed ID: 32437019
[No Abstract] [Full Text] [Related]
2. Baricitinib Is First Approved COVID-19 Immunomodulatory Treatment.
Rubin R
JAMA; 2022 Jun; 327(23):2281. PubMed ID: 35727290
[No Abstract] [Full Text] [Related]
3. An EUA for baricitinib (Olumiant) for COVID-19.
Med Lett Drugs Ther; 2020 Dec; 62(1614):202-203. PubMed ID: 33451175
[No Abstract] [Full Text] [Related]
4. Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals.
Melikhov O; Kruglova T; Lytkina K; Melkonyan G; Prokhorovich E; Putsman G; Rodoman G; Vertkin A; Zagrebneva A; Stebbing J
Ann Rheum Dis; 2021 Sep; 80(9):1245-1246. PubMed ID: 34099486
[No Abstract] [Full Text] [Related]
5. Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease-2019 (COVID-19): A systematic review and meta-analysis.
Lin Z; Niu J; Xu Y; Qin L; Ding J; Zhou L
J Med Virol; 2022 Apr; 94(4):1523-1534. PubMed ID: 34846766
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of spondyloenchondrodysplasia with baricitinib.
Shimizu M; Inoue N; Mizuta M; Irabu H; Okajima M; Honda Y; Nihira H; Izawa K; Yachie A; Wada T
Rheumatology (Oxford); 2021 Feb; 60(2):e44-e46. PubMed ID: 32856090
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Marconi VC; Ramanan AV; de Bono S; Kartman CE; Krishnan V; Liao R; Piruzeli MLB; Goldman JD; Alatorre-Alexander J; de Cassia Pellegrini R; Estrada V; Som M; Cardoso A; Chakladar S; Crowe B; Reis P; Zhang X; Adams DH; Ely EW;
Lancet Respir Med; 2021 Dec; 9(12):1407-1418. PubMed ID: 34480861
[TBL] [Abstract][Full Text] [Related]
8. Audio Interview: Covid-19 Vaccine Fundamentals.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2020 Dec; 383(25):e146. PubMed ID: 33326722
[No Abstract] [Full Text] [Related]
9. Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis.
Pérez-Alba E; Nuzzolo-Shihadeh L; Aguirre-García GM; Espinosa-Mora J; Lecona-Garcia JD; Flores-Pérez RO; Mendoza-Garza M; Camacho-Ortiz A
J Microbiol Immunol Infect; 2021 Oct; 54(5):787-793. PubMed ID: 34294593
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Progression of Acrodermatitis Continua of Hallopeau With Baricitinib.
Han GM; Yang WS; Yang B
JAMA Dermatol; 2021 Apr; 157(4):466-468. PubMed ID: 33656520
[No Abstract] [Full Text] [Related]
11. Perspectives of association Baricitinib/Remdesivir for adults with Covid-19 infection.
Vitiello A; Ferrara F
Mol Biol Rep; 2022 Jan; 49(1):827-831. PubMed ID: 34839450
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis.
Delvino P; Bartoletti A; Monti S; Biglia A; Montecucco C; Carducci M; Ripamonti G; Cavagna L
Rheumatology (Oxford); 2020 Dec; 59(12):e125-e127. PubMed ID: 32353871
[No Abstract] [Full Text] [Related]
13. Repigmentation of vitiligo with oral baricitinib.
Mumford BP; Gibson A; Chong AH
Australas J Dermatol; 2020 Nov; 61(4):374-376. PubMed ID: 32491188
[No Abstract] [Full Text] [Related]
14. Herpes simplex infection in a patient with rheumatoid arthritis treated with baricitinib: a case report.
Valor-Méndez L; Voskens C; Rech J; Kleyer A; Schett G
Rheumatology (Oxford); 2021 Apr; 60(4):e122-e123. PubMed ID: 33141876
[No Abstract] [Full Text] [Related]
15. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.
Rodriguez-Garcia JL; Sanchez-Nievas G; Arevalo-Serrano J; Garcia-Gomez C; Jimenez-Vizuete JM; Martinez-Alfaro E
Rheumatology (Oxford); 2021 Jan; 60(1):399-407. PubMed ID: 33020836
[TBL] [Abstract][Full Text] [Related]
16. Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh.
Hasan MJ; Rabbani R; Anam AM; Huq SMR; Polash MMI; Nessa SST; Bachar SC
BMC Infect Dis; 2021 May; 21(1):427. PubMed ID: 33962573
[TBL] [Abstract][Full Text] [Related]
17. Dupilumab-induced enthesoarthritis and refractory atopic dermatitis successfully treated with baricitinib.
De Stefano L; Bobbio-Pallavicini F; Montecucco C; Bugatti S
Rheumatology (Oxford); 2022 Mar; 61(3):e64-e66. PubMed ID: 34647989
[No Abstract] [Full Text] [Related]
18. Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19.
Izumo T; Kuse N; Awano N; Tone M; Sakamoto K; Takada K; Muto Y; Fujimoto K; Saiki A; Ito Y; Matsumoto H; Inomata M
Respir Investig; 2021 Nov; 59(6):799-803. PubMed ID: 34413006
[TBL] [Abstract][Full Text] [Related]
19. What is the full potential of baricitinib in treating patients with COVID-19?
Biddle K; White J; Sofat N
Expert Rev Clin Immunol; 2022 Jun; 18(6):545-549. PubMed ID: 35486502
[No Abstract] [Full Text] [Related]
20. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.
Richardson P; Griffin I; Tucker C; Smith D; Oechsle O; Phelan A; Rawling M; Savory E; Stebbing J
Lancet; 2020 Feb; 395(10223):e30-e31. PubMed ID: 32032529
[No Abstract] [Full Text] [Related]
[Next] [New Search]
